<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2022-03-11T00:55:21Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8041741" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8041741</identifier>
        <datestamp>2021-04-13</datestamp>
        <setSpec>pheelsevier</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Int J Infect Dis</journal-id>
              <journal-id journal-id-type="iso-abbrev">Int J Infect Dis</journal-id>
              <journal-title-group>
                <journal-title>International Journal of Infectious Diseases</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1201-9712</issn>
              <issn pub-type="epub">1878-3511</issn>
              <publisher>
                <publisher-name>The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8041741</article-id>
              <article-id pub-id-type="pmcid">PMC8041741</article-id>
              <article-id pub-id-type="pmc-uid">8041741</article-id>
              <article-id pub-id-type="pmid">33862210</article-id>
              <article-id pub-id-type="pii">S1201-9712(21)00340-4</article-id>
              <article-id pub-id-type="doi">10.1016/j.ijid.2021.04.029</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>The importance of timely contact tracing — A simulation study</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" id="aut0005">
                  <name>
                    <surname>Mettler</surname>
                    <given-names>Sofia K.</given-names>
                  </name>
                  <xref rid="aff0005" ref-type="aff">a</xref>
                  <xref rid="aff0010" ref-type="aff">b</xref>
                  <xref rid="cor0005" ref-type="corresp">⁎</xref>
                </contrib>
                <contrib contrib-type="author" id="aut0010">
                  <name>
                    <surname>Park</surname>
                    <given-names>Jewel</given-names>
                  </name>
                  <xref rid="aff0015" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author" id="aut0015">
                  <name>
                    <surname>Özbek</surname>
                    <given-names>Orhun</given-names>
                  </name>
                  <xref rid="aff0005" ref-type="aff">a</xref>
                </contrib>
                <contrib contrib-type="author" id="aut0020">
                  <name>
                    <surname>Mettler</surname>
                    <given-names>Linus K.</given-names>
                  </name>
                  <xref rid="aff0020" ref-type="aff">d</xref>
                </contrib>
                <contrib contrib-type="author" id="aut0025">
                  <name>
                    <surname>Ho</surname>
                    <given-names>Po-Han</given-names>
                  </name>
                  <xref rid="aff0010" ref-type="aff">b</xref>
                </contrib>
                <contrib contrib-type="author" id="aut0030">
                  <name>
                    <surname>Rhim</surname>
                    <given-names>Hye Chang</given-names>
                  </name>
                  <xref rid="aff0010" ref-type="aff">b</xref>
                </contrib>
                <contrib contrib-type="author" id="aut0035">
                  <name>
                    <surname>Maathuis</surname>
                    <given-names>Marloes H.</given-names>
                  </name>
                  <xref rid="aff0005" ref-type="aff">a</xref>
                </contrib>
                <aff id="aff0005"><label>a</label>Seminar for Statistics, Department of Mathematics, ETH Zurich, Rämistrasse 101, 8092 Zurich, Switzerland</aff>
                <aff id="aff0010"><label>b</label>School of Public Health, Harvard University, Huntington Ave 677, Boston, MA 02115, United States</aff>
                <aff id="aff0015"><label>c</label>Department of Medicine, Northwestern University Feinberg School of Medicine, 676 N St. Clair Street Arkes Pavilion, Chicago, IL 60611, United States</aff>
                <aff id="aff0020"><label>d</label>Department of Mechanical Engineering, University of California, 6124 Etcheverry Hall, Berkeley, CA 94720, United States</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor0005"><label>⁎</label>Corresponding author at: Seminar for Statistics, Department of Mathematics, ETH Zurich, Rämistrasse 101, 8092 Zurich, Switzerland.</corresp>
              </author-notes>
              <pub-date pub-type="pmc-release">
                <day>13</day>
                <month>4</month>
                <year>2021</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
              <pub-date pub-type="ppub">
                <month>7</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>13</day>
                <month>4</month>
                <year>2021</year>
              </pub-date>
              <volume>108</volume>
              <fpage>309</fpage>
              <lpage>319</lpage>
              <history>
                <date date-type="received">
                  <day>18</day>
                  <month>1</month>
                  <year>2021</year>
                </date>
                <date date-type="rev-recd">
                  <day>8</day>
                  <month>4</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>8</day>
                  <month>4</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2021 The Author(s)</copyright-statement>
                <copyright-year>2021</copyright-year>
                <license>
                  <license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p>
                </license>
              </permissions>
              <abstract id="abs0010">
                <sec>
                  <title>Background</title>
                  <p>While the role of contact tracing in the containment of the COVID-19 epidemic remains important until vaccines are widely available, literature on objectively measurable indicators for the effectiveness of contact tracing is scarce. We suggest the diagnostic serial interval, the time between the diagnosis of the infector and infectee, as a new indicator for the effectiveness of contact tracing.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p>Using an agent-based simulation model, we demonstrate how the diagnostic serial interval correlates with the course of the epidemic. We consider four scenarios of how diagnosis and subsequent isolation are triggered: 1. never, 2. by symptoms, 3. by symptoms and loose contact tracing, 4. by symptoms and tight contact tracing. We further refine scenarios 3 and 4 with different lengths of target diagnostic serial intervals.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>Scenarios 1 and 2 did not yield a notable difference. In scenarios 3 and 4, however, contact tracing led to a decrease of the height of the epidemic as well as the cumulative proportion of infected agents. Generally, the shorter the diagnostic serial interval was, the smaller the peak of the epidemic became, and the more proportion of the population remained susceptible at the end of the epidemic.</p>
                </sec>
                <sec>
                  <title>Conclusion</title>
                  <p>A short target diagnosis interval is critical for contact tracing to be effective in the epidemic control. The diagnosis interval can be used to assess and guide the contact tracing strategy.</p>
                </sec>
              </abstract>
              <kwd-group id="kwd0005">
                <title>Keywords</title>
                <kwd>Diagnostic serial interval</kwd>
                <kwd>Serial interval</kwd>
                <kwd>COVID-19</kwd>
                <kwd>SARS-CoV-2</kwd>
                <kwd>Contact tracing</kwd>
                <kwd>Epidemic control</kwd>
                <kwd>Agent based model</kwd>
              </kwd-group>
            </article-meta>
          </front>
          <body>
            <sec id="sec0005">
              <title>Introduction</title>
              <p id="par0020">In many countries that managed to contain the earlier COVID-19 outbreaks through extensive social distancing or a large-scale lock-down, a second or third wave of the outbreak took place. Although a lock-down or strict social distancing seem to be effective in containing the epidemic, these come with very high socioeconomic costs. The contact tracing strategy of “Diagnose, Trace, Isolate” has been highlighted as a more sustainable alternative in addition to personal hygiene measures such as wearing masks and washing hands (<xref rid="bib0085" ref-type="bibr">Rajan et al., 2020</xref>, <xref rid="bib0115" ref-type="bibr">World Health Organization, 2020a</xref>). While the importance of contact tracing has been emphasized, little literature is available on how to assess the effectiveness of contact tracing. Furthermore, many countries have experienced a surge of new infections even though they have implemented contact tracing strategies, casting doubt around the usefulness of contact tracing (<xref rid="bib0080" ref-type="bibr">Mueller, n.d.</xref>).</p>
              <p id="par0025">Some authors suggested that reducing the delay from infection to diagnosis or from symptom onset to diagnosis is key (<xref rid="bib0090" ref-type="bibr">Rong et al., 2020</xref>). However, these approaches do not offer an objectively measurable parameter to assess the effectiveness of contact tracing, as the time of infection is often unknown and pre- or asymptomatic carriers may account for more than 50% of all transmission events (<xref rid="bib0075" ref-type="bibr">Moghadas et al., 2020</xref>). The total number of infected individuals or disease mortality also do not provide reliable information on the effectiveness of contact tracing since they may depend on other factors such as the number of tests performed, compliance of the public with mitigation measures, the variation in viral strains, weather, the age distribution of the population and medical care quality. The controversial change of testing guidelines by the U.S. Centers for Disease Control and Prevention to not test asymptomatic patients, which was reversed after heavy criticism (<xref rid="bib0100" ref-type="bibr">Sun, 2020</xref>), demonstrated how the absence of an objectively measurable quantity for the effectiveness and usefulness of contact tracing complicates political decision making.</p>
              <p id="par0030">We have previously suggested a novel indicator for the effectiveness of contact tracing that can be easily measured, namely the diagnostic serial interval, which we define as the time between the infector’s diagnosis and the infectee’s diagnosis (<xref rid="bib0065" ref-type="bibr">Mettler et al., 2020</xref>). In this paper, we study the relationship between the diagnostic serial interval and the growth of the epidemic using an agent-based simulation model. The diagnosis of SARS-CoV-2 infection is assumed to be made either via contact tracing and subsequent serial lateral flow antigen (LFA) testing or via symptomatic presentation and polymerase chain reaction (PCR) testing. We find that short diagnostic serial intervals correlate with a successful containment of the epidemic. Our findings imply that (1) fast contact tracing is important, and (2) diagnostic serial intervals can be used as an indicator for the speed of contact tracing.</p>
            </sec>
            <sec id="sec0010">
              <title>Methods</title>
              <p id="par0035">While the majority of currently published simulation studies on COVID-19 are equation-based (<xref rid="bib0005" ref-type="bibr">Adam, 2020</xref>), such models typically do not allow for simulation of infection chains. We therefore employ an agent-based model, by modifying an existing simulation design and code (<xref rid="bib0095" ref-type="bibr">Silva et al., 2020</xref>). Our modifications entail both simplifications and additional features as described in the following paragraphs.</p>
              <sec id="sec0015">
                <title>Simulation design</title>
                <p id="par0040">We simulate the movements of 1000 agents in a two-dimensional space and track the spread of the epidemic within the population. Agents are in one of four states, namely, susceptible, infected, recovered/immune or dead. Unless dead, agents make a random move at every iteration within the predefined space. When susceptible agents come into close contact with an infected agent, they become infected at a given transmission probability. Infected agents develop symptoms after a random incubation time. According to the diagnostic testing triggering condition of the simulation scenario, infected agents may be diagnosed either via contact tracing and daily LFA testing for 5 days or via symptomatic presentation and PCR testing. Diagnosed agents are subsequently placed in isolation for 14 days and released if no longer symptomatic. The symptom status, diagnosis status, and isolation status are updated when certain conditions are fulfilled. One iteration corresponds to one day, and one simulation run (experiment) contains 100 iterations. Algorithm 1 is a pseudocode description of our simulation design. Each operation is explained in detail in Appendix A.</p>
                <p id="par0045">LFA tests detect SARS-CoV-2 infection by collecting a nasal swab sample and running a liquid sample along a surface with reactive molecules. We assumed the use of LFA testing for daily testing for its affordability, detection speed, and ease of use compared to traditional PCR testing (<xref rid="bib0070" ref-type="bibr">Mina et al., 2020</xref>). In December 2020, the United States Food and Drug Administration issued an emergency use authorization for a commercially available LFA test (<xref rid="bib0110" ref-type="bibr">U.S. Food and Drug Administration, 2020</xref>).</p>
                <p id="par0050">
                  <fig id="fig0025">
                    <graphic xlink:href="fx1_lrg"/>
                  </fig>
                </p>
              </sec>
              <sec id="sec0020">
                <title>Epidemiological assumptions</title>
                <p id="par0055"><xref rid="tbl0005" ref-type="table">Table 1</xref>
describes the epidemiological assumptions of our simulation. The incubation time denotes the time between infection and symptom onset. The relative infectiousness refers to the infectiousness at time t relative to the maximum infectiousness <inline-formula><mml:math id="M1" altimg="si3.gif" overflow="scroll"><mml:msub><mml:mrow><mml:mtext>m</mml:mtext><mml:mtext>a</mml:mtext><mml:mtext>x</mml:mtext></mml:mrow><mml:mi>s</mml:mi></mml:msub><mml:mtext> </mml:mtext><mml:mi>g</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mtext> </mml:mtext><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:math></inline-formula>. Here, t is the number of days since the onset of symptoms and can be negative. The probability that an agent infects their close contacts at time t is given by the maximum secondary attack rate of 0.35 multiplied by the relative infectiousness at time t. The detection probability can be thought of as the sensitivity of diagnostic testing. The detection probability by LFA testing is assumed to depend on the relative infectiousness (<xref rid="bib0105" ref-type="bibr">Quilty et al., 2021</xref>). Although the true detection probability may remain high even after the agent is no longer infectious (<xref rid="bib0125" ref-type="bibr">Wölfel et al., 2020</xref>), this assumption does not significantly alter our results as we are mainly interested in case detection during the infectious phase. The detection probability by PCR testing during the symptomatic phase is assumed to be 100% for simplicity.<table-wrap position="float" id="tbl0005"><label>Table 1</label><caption><p>Control parameters — epidemiological assumptions.</p></caption><alt-text id="at0025">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">Epidemiological parameters</th><th align="left">Value</th><th align="left">Reference</th></tr></thead><tbody><tr><td align="left">Population size</td><td align="left">1000</td><td align="left">(Arbitrarily chosen)</td></tr><tr><td align="left">Initial percentage of infected</td><td align="left">0.5%</td><td align="left">(Arbitrarily chosen)</td></tr><tr><td align="left">Initial percentage of immune</td><td align="left">0%</td><td align="left">(Arbitrarily chosen)</td></tr><tr><td align="left">Incubation time distribution</td><td align="left">Log-normal distribution with <inline-formula><mml:math id="M2" altimg="si1.gif" overflow="scroll"><mml:mi>μ</mml:mi><mml:mo>=</mml:mo><mml:mn>1.63</mml:mn></mml:math></inline-formula> and <inline-formula><mml:math id="M3" altimg="si2.gif" overflow="scroll"><mml:mi>σ</mml:mi><mml:mo>=</mml:mo><mml:mn>0.50</mml:mn></mml:math></inline-formula></td><td align="left"><xref rid="bib0060" ref-type="bibr">McAloon et al. (2020)</xref></td></tr><tr><td align="left">Relative infectiousness</td><td align="left"><inline-graphic xlink:href="fx7_lrg.gif"/></td><td align="left"><xref rid="bib0030" ref-type="bibr">Ferretti et al. (2020)</xref></td></tr><tr><td align="left">Maximum secondary attack rate</td><td align="left">0.35</td><td align="left"><xref rid="bib0055" ref-type="bibr">Liu et al. (2020)</xref></td></tr><tr><td align="left">Detection probability</td><td align="left">By LFA testing after contact tracing</td><td align="left"><xref rid="bib0105" ref-type="bibr">Quilty et al. (2021)</xref> (for simplicity)</td></tr><tr><td align="left"/><td align="left"><inline-graphic xlink:href="fx8_lrg.gif"/></td><td align="left"/></tr><tr><td align="left"/><td align="left">By PCR testing while symptomatic 100%</td><td align="left"/></tr><tr><td align="left">Time to recovery</td><td align="left">11.5 days after symptom onset unless dead</td><td align="left"><xref rid="bib0045" ref-type="bibr">Lechien et al. (2020)</xref></td></tr><tr><td align="left">Infection fatality ratio (IFR)</td><td align="left">1%</td><td align="left"><xref rid="bib0120" ref-type="bibr">World Health Organization (2020b)</xref></td></tr></tbody></table></table-wrap></p>
              </sec>
              <sec id="sec0025">
                <title>Simplicity assumptions</title>
                <p id="par0060">For the purpose of simplicity, we did not consider truly asymptomatic transmissions, i.e., agents who never develop symptoms. Also, we assume that every symptomatic patient either recovers and becomes immune or dies after 11.5 days of symptom duration. Furthermore, isolated agents are assumed not to infect others. We do not consider isolation of individuals without a diagnostic confirmation nor precautionary quarantine.</p>
              </sec>
              <sec id="sec0030">
                <title>Scenarios</title>
                <p id="par0065">We consider the following four scenarios as diagnostic testing triggering conditions.</p>
                <p id="par0070"><bold>Scenario 1</bold> Never (do nothing).</p>
                <p id="par0075"><bold>Scenario 2</bold> Time since symptom onset is ≥3 days (only symptom-based testing).</p>
                <p id="par0080"><bold>Scenario 3</bold> Time since symptom onset is ≥3 days or Infector’s Time since diagnosis is ≥5 days (loose contact tracing).</p>
                <p id="par0085"><bold>Scenario 4</bold> Time since symptom onset is ≥3 days or Infector’s Time since diagnosis is ≥2 days (tight contact tracing).</p>
                <p id="par0090">The scenarios where the Time since diagnosis of an infector is given as a diagnosis triggering condition are to simulate contact tracing. When agents are contact-traced, they undergo daily LFA testing for 5 days and are placed in isolation only if the test result is positive. Agents who are symptomatic for 3 days or longer are diagnosed by PCR testing and subsequently isolated.</p>
              </sec>
              <sec id="sec0035">
                <title>Target and observed diagnostic serial intervals</title>
                <p id="par0095">As the detection probability of the virus by LFA testing is relatively low (65%) during the early phase of infection, not all infectees are diagnosed on the day they are contact-traced. For example, even though infectees are contact-traced 2 days after the infector’s diagnosis in scenario 4, the observed diagnostic serial interval may be greater than 2 days, because the virus was not detected by earlier tests. We call this contact-tracing interval of 2 days for scenario 4, or 5 days for scenario 3, the <italic>target diagnostic serial interval</italic>. We use the terms <italic>observed diagnostic serial interval</italic> and <italic>diagnostic serial interval</italic> interchangeably.</p>
              </sec>
              <sec id="sec0040">
                <title>Simulation output</title>
                <p id="par0100">After 100 iterations, two data sets are returned. The first data set contains all agent variables at every iteration. The second data set contains summary statistics of the overall population at each iteration. Using the first data set, the clinical onset serial intervals and diagnostic serial intervals are calculated. The second data set is used to visualize the dynamic development of the epidemic over time.</p>
                <p id="par0105">All simulations are performed using Python version 3.7.1. The resulting simulated data are analyzed using the software R version 4.0.2. All code is available on our github repository (<ext-link ext-link-type="uri" xlink:href="https://github.com/DSI-COVID-Simulation/code/" id="intr0005">https://github.com/DSI-COVID-Simulation/code/</ext-link>).</p>
              </sec>
            </sec>
            <sec id="sec0045">
              <title>Results</title>
              <p id="par0110">The basic reproductive numbers, effective reproductive numbers, and distribution of contacts in scenario 1 can be found in Appendix B.</p>
              <p id="par0115">The epidemic development in each scenario is shown in <xref rid="fig0005" ref-type="fig">Figure 1</xref>
. As each simulation run entails a certain degree of randomness, each scenario is run 100 times with the same initial conditions to show stochastic variation. The ranges between the 5th and 95th percentiles as well as the median values are shown.<fig id="fig0005"><label>Figure 1</label><caption><p>(a) Scenario 1: do nothing. (b) Scenario 2: only symptom-based testing. (c) Scenario 3: loose contact tracing. (d) Scenario 4: tight contact tracing. The solid lines are the median values over all 100 simulations and the shadowed areas represent the 5th–95th percentiles.</p></caption><alt-text id="at0005">Figure 1</alt-text><graphic xlink:href="gr1_lrg"/></fig></p>
              <sec id="sec0050">
                <title>Dynamic of the epidemic</title>
                <sec id="sec0055">
                  <title>Scenario 1. Nothing triggers diagnostic testing (do nothing)</title>
                  <p id="par0120">The first scenario we consider is the “do nothing” scenario. As shown in <xref rid="fig0005" ref-type="fig">Figure 1</xref>(a) the epidemic reaches a peak when 49.0% of the population are infected. The epidemic ends with no infected individuals when immunity is at 84.1% of the population, which is often referred to as herd immunity, leaving only 15.1% of the population susceptible. Assuming an infection fatality ratio of 1%, 0.8% of the population die in this scenario.</p>
                </sec>
                <sec id="sec0060">
                  <title>Scenario 2. Symptom duration of 3 days or longer triggers diagnostic testing (only symptom-based testing)</title>
                  <p id="par0125">In the second scenario patients are diagnosed and subsequently isolated if they had symptoms for 3 days. The epidemic reaches its peak when 45.0% of the population are infected. Interestingly, while 35.2% of the population are isolated at maximum in contrast to no isolation in scenario 1, the epidemic ends after infecting 80.1% of the population in total and causing death in 0.8% of the population, showing little difference to the first scenario.</p>
                </sec>
                <sec id="sec0065">
                  <title>Scenario 3. Symptom duration of 3 days or longer or infector’s time since diagnosis of 5 days or longer trigger diagnostic testing (loose contact tracing)</title>
                  <p id="par0130">The third scenario simulates a contact tracing strategy with a target diagnostic serial interval of 5 days on top of the symptom duration condition defined in scenario 2. The epidemic is contained after reaching a maximum proportion of infected individuals of 34.2%. The epidemic ends after infecting 68.0% of the population and causing death in 0.7% of the population.</p>
                </sec>
                <sec id="sec0070">
                  <title>Scenario 4. Symptom duration of 3 days or longer or infector’s time since diagnosis of 2 days or longer trigger diagnostic testing (tight contact tracing)</title>
                  <p id="par0135">In the last scenario the target diagnostic serial interval is shortened to 2 days. The outbreak peaks with 4.2% of the population infected and 4.2% of the population isolated. The epidemic ends after infecting only 10.5% of the population and causing death in 0.1% of the population.</p>
                  <p id="par0140">Interesting to note in <xref rid="fig0005" ref-type="fig">Figure 1</xref> is the time shift between the curve of infected agents and that of isolated agents in scenarios 2–4. It visualizes that the shortened target diagnostic serial interval leads to a smaller time shift between the curves of infected and isolated agents. This leads to the containment of the epidemic without reaching herd immunity.</p>
                </sec>
              </sec>
              <sec id="sec0075">
                <title>Cumulative proportion of cases with known transmission routes</title>
                <p id="par0145"><xref rid="fig0010" ref-type="fig">Figure 2</xref>
shows the cumulative proportion of cases with known transmission routes for scenarios 3 (loose contact tracing) and 4 (tight contact tracing). Cases are considered to have known transmission routes when they were diagnosed via contact tracing. The proportion of cases with known transmission routes is lower in scenario 3 than in scenario 4, indicating that scenario 3 leads to a larger proportion of cases spreading outside of the surveillance system.<fig id="fig0010"><label>Figure 2</label><caption><p>The cumulative proportion of cases with known transmission routes for scenario 3 with the target diagnostic serial interval of 5 days (a) and for scenario 4 with the target diagnostic serial interval of 2 days (b). The solid lines are the median values over all 100 simulations, and the shadowed areas show the value ranges between the 5th and 95th percentiles.</p></caption><alt-text id="at0010">Figure 2</alt-text><graphic xlink:href="gr2_lrg"/></fig></p>
              </sec>
              <sec id="sec0080">
                <title>The serial intervals</title>
                <p id="par0150">Using the simulation data, we compare the transmission serial interval (TSI), the clinical onset serial interval (COSI), and the diagnostic serial interval (DSI). The transmission serial interval, or the generation time, is the time between the infection events of the infector and the infectee (<xref rid="bib0035" ref-type="bibr">Fine, 2003</xref>). The clinical onset serial interval, commonly referred as the serial interval, is the time between the onset of symptoms of the infector and the infectee (<xref rid="bib0035" ref-type="bibr">Fine, 2003</xref>). The diagnostic serial interval is defined as the time between the infector’s diagnosis and the infectee’s diagnosis (<xref rid="bib0065" ref-type="bibr">Mettler et al., 2020</xref>). The latter two intervals are calculated using the agents’ attributes at the end of the simulation using the formulae in Appendix C.</p>
                <p id="par0155"><xref rid="fig0015" ref-type="fig">Figure 3</xref>
shows histograms and estimated density functions of the transmission serial interval, the clinical onset serial interval, and the diagnostic serial interval in each scenario aggregated from all 100 simulations. <xref rid="tbl0010" ref-type="table">Table 2</xref>
shows the means and standard deviations of the three types of serial intervals.<fig id="fig0015"><label>Figure 3</label><caption><p>Histograms of the transmission serial interval, clinical onset serial interval and diagnostic serial interval of each scenario, from all 100 simulations. The solid lines are density estimates.</p></caption><alt-text id="at0015">Figure 3</alt-text><graphic xlink:href="gr3_lrg"/></fig><table-wrap position="float" id="tbl0010"><label>Table 2</label><caption><p>The mean values of transmission, clinical onset and diagnostic serial intervals for each scenario. The standard deviations are shown in parentheses.</p></caption><alt-text id="at0030">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Scenario 1</th><th align="left">Scenario 2</th><th align="left">Scenario 3</th><th align="left">Scenario 4</th></tr></thead><tbody><tr><td align="left">Transmission serial interval</td><td align="left">5.52 (3.49)</td><td align="left">5.26 (3.24)</td><td align="left">4.56 (2.71)</td><td align="left">4.29 (3.79)</td></tr><tr><td align="left">Clinical onset serial interval</td><td align="left">5.81 (3.87)</td><td align="left">5.47 (3.58)</td><td align="left">5.27 (3.53)</td><td align="left">4.84 (3.46)</td></tr><tr><td align="left">Diagnostic serial interval</td><td align="left">– (–)</td><td align="left">5.47 (3.60)</td><td align="left">4.54 (2.34)</td><td align="left">3.14 (3.31)</td></tr></tbody></table></table-wrap></p>
                <p id="par0160">The distribution of the diagnostic serial interval in scenario 2 (<xref rid="fig0015" ref-type="fig">Figure 3</xref>(b)) is similar to that of the clinical onset serial interval. This is expected as diagnostic testing is only triggered by a symptom duration of 3 days or longer in scenario 2. In scenarios 3 and 4, the diagnostic serial intervals are targeted to be at 5 days and 2 days, respectively, and accordingly result in distributions shown in <xref rid="fig0015" ref-type="fig">Figure 3</xref>(c) and (d).</p>
                <p id="par0165">It is interesting to note that the distributions of transmission serial interval and clinical onset serial interval depend on the mitigation strategies. The stricter the mitigation measures are, the shorter all three types of serial intervals become. This is likely due to the mitigation-based selection for infector-infectee pairs with shorter serial intervals because under mitigation measures, less transmissions occur in the later phase of the infector’s course of infection. This may explain the variation of reported serial intervals in different countries.</p>
              </sec>
              <sec id="sec0085">
                <title>The target diagnostic serial interval and containment of the epidemic</title>
                <p id="par0170">We ran a series of simulations with varying target diagnostic serial intervals from 0 day to 10 days while keeping the symptom-based testing condition at a symptom duration of 3 days or longer as in scenarios 3 and 4. For each target diagnostic serial interval, 100 simulations were performed.</p>
                <p id="par0175"><xref rid="fig0020" ref-type="fig">Figure 4</xref>
(a) shows how the observed mean diagnostic serial interval is correlated with the target diagnostic serial interval. The variation of the observed mean diagnostic serial interval is larger toward shorter target diagnostic serial intervals because the number of infected is small. As target diagnostic serial intervals become longer, the observed diagnostic serial intervals plateau at around 5–6 days, because more people are diagnosed due to symptoms rather than contact tracing.<fig id="fig0020"><label>Figure 4</label><caption><p>The relationships between the target diagnostic serial interval and (a) the observed mean diagnostic serial interval, (b) the proportion of infected agents at the peak of the epidemic and (c) the cumulative proportion of infected agents at the end of the epidemic. Each point represents the result of one simulation run.</p></caption><alt-text id="at0020">Figure 4</alt-text><graphic xlink:href="gr4_lrg"/></fig></p>
                <p id="par0180"><xref rid="fig0020" ref-type="fig">Figure 4</xref>(b) and (c) show the relationship between the target diagnostic serial interval and epidemic control. The effect of contact tracing is shown to change drastically between target diagnostic serial intervals of 2 days and 6 days. For example, an increase in the target diagnostic serial interval from 3 days to 4 days (which corresponds to a mean observed diagnostic serial interval of 3.5 and 4.0, respectively) is associated with an increase in the proportion of infected agents at the height of the epidemic from 13.3% to 26.8%. Meanwhile, the cumulative proportion of infected individuals at the end of the epidemic increases from 32.1% to 57.1%.</p>
              </sec>
            </sec>
            <sec id="sec0090">
              <title>Discussion</title>
              <p id="par0185">Simulation studies are a valuable tool for planning public health interventions and assessing their potential impacts. They are especially useful when dealing with imminent public health crises such as the current COVID-19 pandemic. Our simulation study shows how timely contact tracing can help contain the current pandemic, the effectiveness of which can be measured by the diagnostic serial interval together with the proportion of cases with unknown transmission routes. We conjectured in our previous publication that shortening the diagnostic serial interval below the transmission serial interval will break the infection chain and contribute to the containment of the epidemic (<xref rid="bib0065" ref-type="bibr">Mettler et al., 2020</xref>). The results of this simulation study are in line with this conjecture. Our study suggests that once the number of daily infection cases is brought down by a lock-down and extensive social distancing measures, the strategy of “Diagnose, Trace, Isolate” can be employed as a sustainable long-term measure for epidemic containment in addition to continuing personal hygiene measures. Considering that large-scale quarantine and isolation of individuals correlates with socioeconomic costs (<xref rid="bib0020" ref-type="bibr">Chu et al., 2020</xref>), extensive contact tracing efforts would inflict the least socioeconomic consequences by reducing the number of individuals put in isolation/quarantine.</p>
              <p id="par0190">The second scenario, in which diagnostic testing is triggered after three days of symptom onset, was the strategy implemented in some parts of the world in the early phase of the pandemic. Using the most recently reported information on the epidemiological characteristics of the virus (incubation and infectiousness profile), our simulation shows that a mere symptom-based approach brings little benefit compared to the “do nothing” strategy, albeit perhaps reducing the strain on the health care system by delaying the peak of the epidemic and reducing its height.</p>
              <p id="par0195">While there have been promising results regarding possible vaccines, contact tracing will remain important until vaccines are widely administered. In particular, many low income countries will not be able to vaccinate most of their populations in 2021 (<xref rid="bib0025" ref-type="bibr">Dyer, 2020</xref>), and contact tracing will continue to be one of the few sustainable measures available against the COVID-19 pandemic in these countries. Our study underlines the importance of <italic>fast</italic> contact tracing. While the contact tracing thoroughness can be measured by the proportion of cases with known transmission routes, the diagnostic serial interval provides information on the timeliness of contact tracing. A shorter diagnostic serial interval implies timeliness in various steps of contact tracing, including fast identification of contacts, a short time between identifying contacts and conducting diagnostic tests, and quick return of test results. Our results suggest a close relationship between the epidemic control and the length of the diagnostic serial interval.</p>
              <p id="par0200">We have assumed that LFA testing was used for serial testing of those who have been identified through contact tracing. Nasopharyngeal PCR testing is considered a gold standard in diagnosing SARS-CoV-2 infection; however, it is not suitable for daily testing due to its high cost and turnaround time. Although LFA is less sensitive than PCR, this is not so important if the goal is to detect actively infectious patients (<xref rid="bib0070" ref-type="bibr">Mina et al., 2020</xref>). While LFA testing is inexpensive and quick, its effect in reducing transmission may be comparable to a 14-day quarantine, when used as daily serial testing accompanied by isolation of positive individuals (<xref rid="bib0105" ref-type="bibr">Quilty et al., 2021</xref>). LFA testing is a critical component in the response against COVID-19 pandemic especially in resource-limited settings (<xref rid="bib0010" ref-type="bibr">Boum et al., 2021</xref>).</p>
              <p id="par0205">There are several limitations to our simulation study. First, we considered a simplified setting with a small population and a two-dimensional space without complex social structures that can lead to super-spreading events. Second, we use the same maximum secondary attack rate of 35% for all infector-infectee contacts, regardless of the duration and nature of the contact. Current literature suggests a wide range of secondary attack rates ranging from 0.46% to 63.87% (<xref rid="bib0040" ref-type="bibr">Huang et al., 2020</xref>). This is likely due to different definitions of what constitutes close contact. For future studies, we may sub-categorize types of contacts and apply the contact-type specific secondary attack rate accordingly. Third, we assumed all contacts can be traced. The effect of this assumption may be partly offset by lowering the detection probability of LFA testing. Fourth, we did not consider asymptomatic carriers who never develop symptoms. According to recent literature, a significant portion of asymptomatic carriers remain asymptomatic (<xref rid="bib0130" ref-type="bibr">Zhou et al., 2020</xref>). However, asymptomatic carriers are less likely to form neutralizing antibodies and any antibodies formed tend to disappear quickly (<xref rid="bib0050" ref-type="bibr">Lei et al., 2021</xref>). Thus, we conjectured that asymptomatic carriers will contribute minimally in forming herd immunity. In addition, asymptomatic carriers are 65% less likely to transmit the virus than those with symptomatic infections (<xref rid="bib0015" ref-type="bibr">Buitrago-Garcia et al., 2020</xref>). For these reasons we decided to exclude truly asymptomatic carriers from our analysis. Furthermore, the number of deaths in our simulation is not a reliable estimate of the mortality for the following reasons. First, age is not considered for the purpose of simplicity. Second, the infection fatality ratio of 1% (<xref rid="bib0120" ref-type="bibr">World Health Organization, 2020b</xref>) is based on the assumption that proper medical care is provided. Our simulation, however, did not take medical care capacity into account. Finally, we assumed that all individuals are perfectly compliant with the isolation policy and that no infection occurs during isolation.</p>
              <p id="par0210">The largest changes in the benefits of contact tracing are observed in a range of target diagnostic serial intervals between 2 days and 6 days with an inflection point lying somewhere between 3 and 4 days (<xref rid="fig0020" ref-type="fig">Figure 4</xref>) for this simulation setting. The role of the diagnostic serial interval in disease control should be studied further in relation to epidemiological parameters such as the incubation period, infectiousness profile or detection probability, which can be then generalized to other infectious diseases.</p>
            </sec>
            <sec id="sec0095">
              <title>Patient or public involvement statement and ethics committee approval</title>
              <p id="par0215">Our research is based on simulation data and does not require to involve patients or the public in the design, or conduct, or reporting, or dissemination plans. Our research does not require ethics committee approval.</p>
            </sec>
            <sec id="sec0100">
              <title>Conflict of interest statement</title>
              <p id="par0220">All authors declare no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.</p>
            </sec>
            <sec id="sec0105">
              <title>Funding source</title>
              <p id="par0225">There is no funding source to declare.</p>
            </sec>
          </body>
          <back>
            <ref-list id="bibl0005">
              <title>References</title>
              <ref id="bib0005">
                <element-citation publication-type="journal" id="sbref0005">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Adam</surname>
                      <given-names>D.</given-names>
                    </name>
                  </person-group>
                  <article-title>Modelling the pandemic — the simulations driving the world’s response to COVID-19</article-title>
                  <source>Nature</source>
                  <volume>580</volume>
                  <year>2020</year>
                  <fpage>316</fpage>
                  <lpage>318</lpage>
                  <pub-id pub-id-type="pmid">32242115</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0010">
                <element-citation publication-type="journal" id="sbref0010">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Boum</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>Fai</surname>
                      <given-names>K.N.</given-names>
                    </name>
                    <name>
                      <surname>Nicolay</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Mboringong</surname>
                      <given-names>A.B.</given-names>
                    </name>
                    <name>
                      <surname>Bebell</surname>
                      <given-names>L.M.</given-names>
                    </name>
                    <name>
                      <surname>Ndifon</surname>
                      <given-names>M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study</article-title>
                  <source>Lancet Infect Dis</source>
                  <year>2021</year>
                  <pub-id pub-id-type="doi">10.1016/S1473-3099(21)00132-8</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0015">
                <element-citation publication-type="journal" id="sbref0015">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Buitrago-Garcia</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Egli-Gany</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Counotte</surname>
                      <given-names>M.J.</given-names>
                    </name>
                    <name>
                      <surname>Hossmann</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Imeri</surname>
                      <given-names>H.</given-names>
                    </name>
                    <name>
                      <surname>Ipekci</surname>
                      <given-names>A.M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis</article-title>
                  <source>PLoS Med</source>
                  <volume>17</volume>
                  <issue>9</issue>
                  <year>2020</year>
                  <object-id pub-id-type="publisher-id">e1003346</object-id>
                </element-citation>
              </ref>
              <ref id="bib0020">
                <element-citation publication-type="journal" id="sbref0020">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chu</surname>
                      <given-names>I.Y.H.</given-names>
                    </name>
                    <name>
                      <surname>Alam</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Larson</surname>
                      <given-names>H.J.</given-names>
                    </name>
                    <name>
                      <surname>Lin</surname>
                      <given-names>L.</given-names>
                    </name>
                  </person-group>
                  <article-title>Social consequences of mass quarantine during epidemics: a systematic review with implications for the COVID-19 response</article-title>
                  <source>J Travel Med</source>
                  <volume>27</volume>
                  <issue>October (7)</issue>
                  <year>2020</year>
                  <fpage>taaa192</fpage>
                  <pub-id pub-id-type="doi">10.1093/jtm/taaa192</pub-id>
                  <pub-id pub-id-type="pmid">33051660</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0025">
                <element-citation publication-type="journal" id="sbref0025">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dyer</surname>
                      <given-names>O.</given-names>
                    </name>
                  </person-group>
                  <article-title>Covid-19: Many poor countries will see almost no vaccine next year, aid groups warn</article-title>
                  <source>BMJ</source>
                  <volume>371</volume>
                  <year>2020</year>
                  <fpage>m4809</fpage>
                  <pub-id pub-id-type="doi">10.1136/bmj.m4809</pub-id>
                  <pub-id pub-id-type="pmid">33310819</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0030">
                <element-citation publication-type="journal" id="sbref0030">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ferretti</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Ledda</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Wymant</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Zhao</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Ledda</surname>
                      <given-names>V.</given-names>
                    </name>
                    <name>
                      <surname>Abeler-Dörner</surname>
                      <given-names>L.</given-names>
                    </name>
                  </person-group>
                  <article-title>The timing of covid-19 transmission</article-title>
                  <source>medRxiv</source>
                  <year>2020</year>
                  <pub-id pub-id-type="doi">10.1101/2020.09.04.20188516</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0035">
                <element-citation publication-type="journal" id="sbref0035">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fine</surname>
                      <given-names>P.E.</given-names>
                    </name>
                  </person-group>
                  <article-title>The interval between successive cases of an infectious disease</article-title>
                  <source>Am J Epidemiol</source>
                  <volume>158</volume>
                  <year>2003</year>
                  <fpage>1039</fpage>
                  <lpage>1047</lpage>
                  <pub-id pub-id-type="doi">10.1093/aje/kwg251</pub-id>
                  <pub-id pub-id-type="pmid">14630599</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0040">
                <element-citation publication-type="journal" id="sbref0040">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Huang</surname>
                      <given-names>Y.-T.</given-names>
                    </name>
                    <name>
                      <surname>Tu</surname>
                      <given-names>Y.-K.</given-names>
                    </name>
                    <name>
                      <surname>Lai</surname>
                      <given-names>P.-C.</given-names>
                    </name>
                  </person-group>
                  <article-title>Estimation of the secondary attack rate of COVID-19 using proportional meta-analysis of nationwide contact tracing data in Taiwan</article-title>
                  <source>J Microbiol Immunol Infect</source>
                  <volume>54</volume>
                  <issue>1</issue>
                  <year>2020</year>
                  <fpage>89</fpage>
                  <lpage>92</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jmii.2020.06.003</pub-id>
                  <pub-id pub-id-type="pmid">32553448</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0045">
                <element-citation publication-type="journal" id="sbref0045">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lechien</surname>
                      <given-names>J.R.</given-names>
                    </name>
                    <name>
                      <surname>Chiesa-Estomba</surname>
                      <given-names>C.M.</given-names>
                    </name>
                    <name>
                      <surname>Place</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Van Laethem</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>Cabaraux</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Mat</surname>
                      <given-names>Q.</given-names>
                    </name>
                  </person-group>
                  <article-title>Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019</article-title>
                  <source>J Intern Med</source>
                  <volume>288</volume>
                  <year>2020</year>
                  <fpage>335</fpage>
                  <lpage>344</lpage>
                  <pub-id pub-id-type="doi">10.1111/joim.13089</pub-id>
                  <pub-id pub-id-type="pmid">32352202</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0050">
                <element-citation publication-type="journal" id="sbref0050">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lei</surname>
                      <given-names>Q.</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>Hou</surname>
                      <given-names>H.Y.</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>F.</given-names>
                    </name>
                    <name>
                      <surname>Ouyang</surname>
                      <given-names>Z.Q.</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>Y.</given-names>
                    </name>
                  </person-group>
                  <article-title>Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections</article-title>
                  <source>Allergy</source>
                  <volume>76</volume>
                  <issue>2</issue>
                  <year>2021</year>
                  <fpage>551</fpage>
                  <lpage>561</lpage>
                  <pub-id pub-id-type="pmid">33040337</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0055">
                <element-citation publication-type="journal" id="sbref0055">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Liu</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>Eggo</surname>
                      <given-names>R.M.</given-names>
                    </name>
                    <name>
                      <surname>Kucharski</surname>
                      <given-names>A.J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Secondary attack rate and superspreading events for SARS-CoV-2</article-title>
                  <source>Lancet</source>
                  <volume>395</volume>
                  <year>2020</year>
                  <fpage>e47</fpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30462-1</pub-id>
                  <pub-id pub-id-type="pmid">32113505</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0060">
                <element-citation publication-type="journal" id="sbref0060">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McAloon</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Collins</surname>
                      <given-names>Á.</given-names>
                    </name>
                    <name>
                      <surname>Hunt</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Barber</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Byrne</surname>
                      <given-names>A.W.</given-names>
                    </name>
                    <name>
                      <surname>Butler</surname>
                      <given-names>F.</given-names>
                    </name>
                  </person-group>
                  <article-title>Incubation period of COVID-19: a rapid systematic review and meta-analysis of observational research</article-title>
                  <source>BMJ Open</source>
                  <volume>10</volume>
                  <year>2020</year>
                  <object-id pub-id-type="publisher-id">e039652</object-id>
                  <pub-id pub-id-type="doi">10.1136/bmjopen-2020-039652</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0065">
                <element-citation publication-type="journal" id="sbref0065">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mettler</surname>
                      <given-names>S.K.</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Maathuis</surname>
                      <given-names>M.H.</given-names>
                    </name>
                  </person-group>
                  <article-title>Diagnostic serial interval as a novel indicator for contact tracing effectiveness exemplified with the SARS-CoV-2/COVID-19 outbreak in South Korea</article-title>
                  <source>Int J Infect Dis</source>
                  <volume>99</volume>
                  <year>2020</year>
                  <fpage>346</fpage>
                  <lpage>351</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ijid.2020.07.068</pub-id>
                  <pub-id pub-id-type="pmid">32771634</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0070">
                <element-citation publication-type="journal" id="sbref0070">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mina</surname>
                      <given-names>M.J.</given-names>
                    </name>
                    <name>
                      <surname>Parker</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Larremore</surname>
                      <given-names>D.B.</given-names>
                    </name>
                  </person-group>
                  <article-title>Rethinking Covid-19 test sensitivity—a strategy for containment</article-title>
                  <source>N Eng J Med</source>
                  <volume>383</volume>
                  <issue>22</issue>
                  <year>2020</year>
                  <fpage>e120</fpage>
                </element-citation>
              </ref>
              <ref id="bib0075">
                <element-citation publication-type="journal" id="sbref0075">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Moghadas</surname>
                      <given-names>S.M.</given-names>
                    </name>
                    <name>
                      <surname>Fitzpatrick</surname>
                      <given-names>M.C.</given-names>
                    </name>
                    <name>
                      <surname>Sah</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Pandey</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Shoukat</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Singer</surname>
                      <given-names>B.H.</given-names>
                    </name>
                  </person-group>
                  <article-title>The implications of silent transmission for the control of covid-19 outbreaks</article-title>
                  <source>Proc Natl Acad Sci U S A</source>
                  <volume>117</volume>
                  <year>2020</year>
                  <fpage>17513</fpage>
                  <lpage>17515</lpage>
                  <pub-id pub-id-type="doi">10.1073/pnas.2008373117</pub-id>
                  <pub-id pub-id-type="pmid">32632012</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0080">
                <mixed-citation publication-type="other" id="oref0080">Mueller B. Contact tracing, key to reining in the virus, falls flat in the west. New York Times; October 2020.</mixed-citation>
              </ref>
              <ref id="bib0085">
                <element-citation publication-type="journal" id="sbref0085">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rajan</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Cylus</surname>
                      <given-names>J.D.</given-names>
                    </name>
                    <name>
                      <surname>Mckee</surname>
                      <given-names>M.</given-names>
                    </name>
                  </person-group>
                  <article-title>What do countries need to do to implement effective ‘find, test, trace, isolate and support’ systems?</article-title>
                  <source>J R Soc Med</source>
                  <volume>113</volume>
                  <year>2020</year>
                  <fpage>245</fpage>
                  <lpage>250</lpage>
                  <pub-id pub-id-type="doi">10.1177/0141076820939395</pub-id>
                  <pub-id pub-id-type="pmid">32663428</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0090">
                <element-citation publication-type="journal" id="sbref0090">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rong</surname>
                      <given-names>X.M.</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>di Chu</surname>
                      <given-names>H.</given-names>
                    </name>
                    <name>
                      <surname>Fan</surname>
                      <given-names>M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Effect of delay in diagnosis on transmission of COVID-19</article-title>
                  <source>Math Biosci Eng</source>
                  <volume>17</volume>
                  <year>2020</year>
                  <fpage>2725</fpage>
                  <lpage>2740</lpage>
                  <pub-id pub-id-type="doi">10.3934/mbe.2020149</pub-id>
                  <pub-id pub-id-type="pmid">32233563</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0095">
                <element-citation publication-type="journal" id="sbref0095">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Silva</surname>
                      <given-names>P.C.L.</given-names>
                    </name>
                    <name>
                      <surname>Batista</surname>
                      <given-names>P.V.C.</given-names>
                    </name>
                    <name>
                      <surname>Lima</surname>
                      <given-names>H.S.</given-names>
                    </name>
                    <name>
                      <surname>Alves</surname>
                      <given-names>M.A.</given-names>
                    </name>
                    <name>
                      <surname>Guimarães</surname>
                      <given-names>F.G.</given-names>
                    </name>
                    <name>
                      <surname>Silva</surname>
                      <given-names>R.C.P.</given-names>
                    </name>
                  </person-group>
                  <article-title>COVID-ABS: an agent-based model of COVID-19 epidemic to simulate health and economic effects of social distancing interventions</article-title>
                  <source>Chaos Soliton Fract</source>
                  <volume>139</volume>
                  <year>2020</year>
                  <object-id pub-id-type="publisher-id">110088</object-id>
                  <pub-id pub-id-type="doi">10.1016/j.chaos.2020.110088</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0100">
                <element-citation publication-type="book" id="sbref0100">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sun</surname>
                      <given-names>L.</given-names>
                    </name>
                  </person-group>
                  <chapter-title>CDC reverses controversial coronavirus guidelines for testing people without symptoms</chapter-title>
                  <year>2020</year>
                  <publisher-name>The Washington Post</publisher-name>
                  <comment>19 September 2020</comment>
                </element-citation>
              </ref>
              <ref id="bib0105">
                <element-citation publication-type="journal" id="sbref0105">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Quilty</surname>
                      <given-names>B.J.</given-names>
                    </name>
                    <name>
                      <surname>Clifford</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Hellewell</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Russell</surname>
                      <given-names>T.W.</given-names>
                    </name>
                    <name>
                      <surname>Kucharski</surname>
                      <given-names>A.J.</given-names>
                    </name>
                    <name>
                      <surname>Flasche</surname>
                      <given-names>S.</given-names>
                    </name>
                  </person-group>
                  <article-title>Quarantine and testing strategies in contact tracing for SARS-CoV-2: a modelling study</article-title>
                  <source>Lancet Public Health</source>
                  <volume>6</volume>
                  <issue>March (3)</issue>
                  <year>2021</year>
                  <fpage>e175</fpage>
                  <lpage>e183</lpage>
                  <pub-id pub-id-type="doi">10.1016/S2468-2667(20)30308-X</pub-id>
                  <pub-id pub-id-type="pmid">33484644</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0110">
                <element-citation publication-type="book" id="sbref0110">
                  <person-group person-group-type="author">
                    <name>
                      <surname>U.S. Food and Drug Administration</surname>
                    </name>
                  </person-group>
                  <chapter-title>Coronavirus (COVID-19) update: FDA authorizes antigen test as first over-the-counter fully at-home diagnostic test for COVID-19</chapter-title>
                  <year>2020</year>
                  <comment>Retrieved from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-antigen-test-first-over-counter-fully-home-diagnostic on 1 April 2021</comment>
                </element-citation>
              </ref>
              <ref id="bib0115">
                <element-citation publication-type="book" id="sbref0115">
                  <person-group person-group-type="author">
                    <name>
                      <surname>World Health Organization</surname>
                    </name>
                  </person-group>
                  <chapter-title>Director-General’s opening remarks at the media briefing on COVID-19</chapter-title>
                  <comment>16 March 2020</comment>
                  <year>2020</year>
                </element-citation>
              </ref>
              <ref id="bib0120">
                <element-citation publication-type="book" id="sbref0120">
                  <person-group person-group-type="author">
                    <name>
                      <surname>World Health Organization</surname>
                    </name>
                  </person-group>
                  <chapter-title>Estimating mortality from COVID-19</chapter-title>
                  <comment>4 August 2020</comment>
                  <year>2020</year>
                </element-citation>
              </ref>
              <ref id="bib0125">
                <element-citation publication-type="journal" id="sbref0125">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wölfel</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Corman</surname>
                      <given-names>V.M.</given-names>
                    </name>
                    <name>
                      <surname>Guggemos</surname>
                      <given-names>W.</given-names>
                    </name>
                    <name>
                      <surname>Seilmaier</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Zange</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Müller</surname>
                      <given-names>M.A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Virological assessment of hospitalized patients with covid-2019</article-title>
                  <source>Nature</source>
                  <volume>581</volume>
                  <year>2020</year>
                  <fpage>465</fpage>
                  <lpage>469</lpage>
                  <pub-id pub-id-type="doi">10.1038/s41586-020-2196-x</pub-id>
                  <pub-id pub-id-type="pmid">32235945</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0130">
                <element-citation publication-type="journal" id="sbref0130">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zhou</surname>
                      <given-names>X.</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>W.</given-names>
                    </name>
                  </person-group>
                  <article-title>Follow-up of asymptomatic patients with SARS-CoV-2 infection</article-title>
                  <source>Clin Microbiol Infect</source>
                  <volume>26</volume>
                  <year>2020</year>
                  <fpage>957</fpage>
                  <lpage>959</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.cmi.2020.03.024</pub-id>
                  <pub-id pub-id-type="pmid">32234453</pub-id>
                </element-citation>
              </ref>
            </ref-list>
            <sec id="sec0110">
              <label>Appendix A</label>
              <title>Simulation design</title>
              <sec id="sec0115">
                <label>1</label>
                <title>) Initialization</title>
                <p id="par0230">A two-dimensional space is defined and populated with a given number of agents. Each agent has several attributes as listed in Table 3.</p>
                <p id="par0235">
                  <italic>Agent attributes and their value ranges with initial values in italic. Time is measured in terms of the number of iterations (days).</italic>
                  <table-wrap position="anchor" id="tbl0015">
                    <table frame="hsides" rules="groups">
                      <thead>
                        <tr>
                          <th align="left">Agent attributes</th>
                          <th align="left">Possible values</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left">ID</td>
                          <td align="left">{<inline-formula><mml:math id="M4" altimg="si4.gif" overflow="scroll"><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mn>3</mml:mn><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mo>.</mml:mo><mml:mo>.</mml:mo><mml:mo>.</mml:mo><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mn>1000</mml:mn></mml:math></inline-formula>}</td>
                        </tr>
                        <tr>
                          <td align="left">Location</td>
                          <td align="left">
                            <inline-formula>
                              <mml:math id="M5" altimg="si5.gif" overflow="scroll">
                                <mml:mo stretchy="false">(</mml:mo>
                                <mml:mi>x</mml:mi>
                                <mml:mo>,</mml:mo>
                                <mml:mtext> </mml:mtext>
                                <mml:mi>y</mml:mi>
                                <mml:mo stretchy="false">)</mml:mo>
                                <mml:mo>∈</mml:mo>
                                <mml:mo>[</mml:mo>
                                <mml:mn>0</mml:mn>
                                <mml:mo>,</mml:mo>
                                <mml:mtext> </mml:mtext>
                                <mml:mn>50</mml:mn>
                                <mml:mo>]</mml:mo>
                                <mml:mo>×</mml:mo>
                                <mml:mo>[</mml:mo>
                                <mml:mn>0</mml:mn>
                                <mml:mo>,</mml:mo>
                                <mml:mtext> </mml:mtext>
                                <mml:mn>50</mml:mn>
                                <mml:mo>]</mml:mo>
                              </mml:math>
                            </inline-formula>
                          </td>
                        </tr>
                        <tr>
                          <td align="left">Infection status</td>
                          <td align="left">{<italic>Susceptible</italic>, Infected, Recovered/Immune, Dead}</td>
                        </tr>
                        <tr>
                          <td align="left">Activity degree</td>
                          <td align="left">{0.3, 1, 3}</td>
                        </tr>
                        <tr>
                          <td align="left">Symptom status</td>
                          <td align="left">{<italic>Presymptomatic</italic>, Symptomatic, Postsymptomatic}</td>
                        </tr>
                        <tr>
                          <td align="left">Diagnosis status</td>
                          <td align="left">{<italic>Undiagnosed</italic>, Diagnosed}</td>
                        </tr>
                        <tr>
                          <td align="left">Isolation status</td>
                          <td align="left">{<italic>No isolation</italic>, Isolated}</td>
                        </tr>
                        <tr>
                          <td align="left">Time since infection</td>
                          <td align="left">{<italic>None</italic>, 0, 1, 2, …}</td>
                        </tr>
                        <tr>
                          <td align="left">Incubation time</td>
                          <td align="left">{<italic>None</italic>, 0,1,2, …}</td>
                        </tr>
                        <tr>
                          <td align="left">Time since symptom onset</td>
                          <td align="left">{<italic>None</italic>, 0, 1, 2, …}</td>
                        </tr>
                        <tr>
                          <td align="left">Time since diagnosis</td>
                          <td align="left">{<italic>None</italic>, 0, 1, 2, …}</td>
                        </tr>
                        <tr>
                          <td align="left">Time since isolation start</td>
                          <td align="left">{<italic>None</italic>, 0, 1, 2, …}</td>
                        </tr>
                        <tr>
                          <td align="left">Infector ID</td>
                          <td align="left">{<italic>None</italic>, 1, 2, …, 1000}</td>
                        </tr>
                        <tr>
                          <td align="left">Transmission serial interval</td>
                          <td align="left">{<italic>None</italic>, 0, 1, 2, …}</td>
                        </tr>
                      </tbody>
                    </table>
                  </table-wrap>
                </p>
                <p id="par0240">Table 4 summarizes the control parameters for the model. It defines the number of agents, the movement amplitude of agents and the distance between two agents that qualifies as close contact.</p>
                <p id="par0245">
                  <italic>Control parameters — model assumptions.</italic>
                  <table-wrap position="anchor" id="tbl0020">
                    <table frame="hsides" rules="groups">
                      <thead>
                        <tr>
                          <th align="left">Model parameters</th>
                          <th align="left">Value</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left">Number of agents</td>
                          <td align="left">1000</td>
                        </tr>
                        <tr>
                          <td align="left">Amplitude of movement</td>
                          <td align="left">Susceptible: 3</td>
                        </tr>
                        <tr>
                          <td align="left"/>
                          <td align="left">Recovered/Immune: 3</td>
                        </tr>
                        <tr>
                          <td align="left"/>
                          <td align="left">Infected: 3</td>
                        </tr>
                        <tr>
                          <td align="left"/>
                          <td align="left">Dead: 0</td>
                        </tr>
                        <tr>
                          <td align="left"/>
                          <td align="left">Isolated: 0</td>
                        </tr>
                        <tr>
                          <td align="left">Distance considered as contact</td>
                          <td align="left">≤1</td>
                        </tr>
                      </tbody>
                    </table>
                  </table-wrap>
                </p>
              </sec>
              <sec id="sec0120">
                <label>2</label>
                <title>) Execution and iterations</title>
                <p id="par0250">At every iteration the functions move, update, contact and diagnosis are executed. This is repeated for a given number of iterations which reflects the number of days of observation. We set the number of iterations to be 100.</p>
                <sec id="sec0125">
                  <title>Move</title>
                  <p id="par0255">We simulate the movements of agents in a simplified manner. At each iteration every agent moves vertically and horizontally by a distance randomly chosen from the standard normal distribution <inline-formula><mml:math id="M6" altimg="si6.gif" overflow="scroll"><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> multiplied by the status-based amplitude of movement and the activity degree of the agent. The activity degree is randomly chosen at the beginning of the simulation for each agent and can be thought of the agent’s personal trait (age, personality, etc.) that determines the relative range of movement of the agent. The positions of agents at time t + 1 are given by <inline-formula><mml:math id="M7" altimg="si7.gif" overflow="scroll"><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>Δ</mml:mi><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:mrow></mml:msub><mml:mo>×</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>p</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>u</mml:mi><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mtext> </mml:mtext><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mtext> </mml:mtext><mml:mi>m</mml:mi><mml:mi>o</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>×</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>y</mml:mi><mml:mtext> </mml:mtext><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>e</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> and <inline-formula><mml:math id="M8" altimg="si8.gif" overflow="scroll"><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>Δ</mml:mi><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:mrow></mml:msub><mml:mo>×</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>p</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>u</mml:mi><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mtext> </mml:mtext><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mtext> </mml:mtext><mml:mi>m</mml:mi><mml:mi>o</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>×</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>y</mml:mi><mml:mtext> </mml:mtext><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>e</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> where <inline-formula><mml:math id="M9" altimg="si9.gif" overflow="scroll"><mml:msub><mml:mi>Δ</mml:mi><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="M10" altimg="si10.gif" overflow="scroll"><mml:msub><mml:mi>Δ</mml:mi><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:mrow></mml:msub></mml:math></inline-formula> are independent realizations of the standard normal distribution. All agents are only able to move within the two-dimensional space defined in the initialization step. Periodic boundary conditions are applied at the boundaries.</p>
                </sec>
                <sec id="sec0130">
                  <title>Update</title>
                  <p id="par0260">At each iteration the Infection status, Symptom status, Isolation status, Time since infection, Time since symptom onset and Time since diagnosis of agents are updated as indicated in Table 5.</p>
                  <p id="par0265"><italic>Agent variables which are updated at every iteration and the conditions for the update</italic>.<table-wrap position="anchor" id="tbl0025"><table frame="hsides" rules="groups"><thead><tr><th align="left">Agent variable</th><th align="left">Update</th><th align="left">Condition</th></tr></thead><tbody><tr><td align="left">Infection status</td><td align="left">Infected → Dead</td><td align="left">Happens with probability IFR (see <xref rid="tbl0005" ref-type="table">Table 1</xref>) if Time since symptom onset is 11.5 days.</td></tr><tr><td align="left"/><td align="left">Infected → Recovered/Immune</td><td align="left">If Time since symptom onset is 11.5 days and agent is not dead.</td></tr><tr><td align="left">Symptom status</td><td align="left">Presymptomatic → Symptomatic</td><td align="left">If Time since infection exceeds Incubation time.</td></tr><tr><td align="left"/><td align="left">Symptomatic → Postsymptomatic</td><td align="left">Happens when Infection status changes from Infected to Recovered/Immune.</td></tr><tr><td align="left">Isolation status</td><td align="left">Isolated → No isolation</td><td align="left">If Time since isolation start is 14 days and Infection status is Recovered/Immune.</td></tr><tr><td align="left"/><td align="left">No isolation → Isolated</td><td align="left">When agent is diagnosed.</td></tr><tr><td align="left">Time since infection</td><td align="left">None → 0</td><td align="left">When agent becomes infected.</td></tr><tr><td align="left"/><td align="left">+1</td><td align="left">At every iteration afterwards.</td></tr><tr><td align="left">Time since symptom onset</td><td align="left">None → 0</td><td align="left">When agent becomes symptomatic.</td></tr><tr><td align="left"/><td align="left">+1</td><td align="left">At every iteration afterwards.</td></tr><tr><td align="left">Time since isolation start</td><td align="left">None → 0</td><td align="left">When agent becomes isolated.</td></tr><tr><td align="left"/><td align="left">+1</td><td align="left">At every iteration afterwards.</td></tr><tr><td align="left">Time since diagnosis</td><td align="left">None → 0</td><td align="left">When agent becomes diagnosed.</td></tr><tr><td align="left"/><td align="left">+1</td><td align="left">At every iteration afterwards.</td></tr></tbody></table></table-wrap></p>
                </sec>
                <sec id="sec0135">
                  <title>Contact</title>
                  <p id="par0270">New contacts occur at every iteration as a result of agents’ movements. If a susceptible agent is located within the predefined contagion distance of an infected agent who is not isolated, the susceptible agent becomes infected at a given probability, namely, the maximum secondary attack rate multiplied by infectiousness as defined in <xref rid="tbl0005" ref-type="table">Table 1</xref>. At the time of contact and subsequent transmission, the Infection status of the newly infected agent is updated from Susceptible to Infected and the Infector ID and Transmission serial interval, which is equivalent to the infector’s Time since infection, are recorded in the attributes of the newly infected agent. The recording of the Infector ID allows for tracking of transmission chains.</p>
                </sec>
                <sec id="sec0140">
                  <title>Diagnosis</title>
                  <p id="par0275">Based on the diagnosis triggering condition chosen for the simulation, agents who are infected and meet the diagnosis triggering condition become diagnosed and subsequently isolated. The variables Diagnosis status and Isolation status are updated from Undiagnosed to Diagnosed and from No isolation to Isolated.</p>
                </sec>
              </sec>
              <sec id="sec0145">
                <label>3</label>
                <title>) Response variables</title>
                <p id="par0280">Table 6 summarizes the response variables of the simulation.</p>
                <p id="par0285">
                  <italic>Response variables</italic>
                  <table-wrap position="anchor" id="tbl0030">
                    <table frame="hsides" rules="groups">
                      <thead>
                        <tr>
                          <th align="left">Response variables</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left">Proportion of susceptible agents at each iteration</td>
                        </tr>
                        <tr>
                          <td align="left">Proportion of infected agents at each iteration</td>
                        </tr>
                        <tr>
                          <td align="left">Proportion of recovered/immune agents at each iteration</td>
                        </tr>
                        <tr>
                          <td align="left">Proportion of dead agents at each iteration</td>
                        </tr>
                        <tr>
                          <td align="left">Proportion of isolated agents at each iteration</td>
                        </tr>
                        <tr>
                          <td align="left">Cumulative proportion of cases with known transmission routes at each iteration</td>
                        </tr>
                        <tr>
                          <td align="left">Transmission serial intervals for all infected individuals</td>
                        </tr>
                        <tr>
                          <td align="left">Clinical onset serial intervals for all symptomatic individuals</td>
                        </tr>
                        <tr>
                          <td align="left">Diagnostic serial intervals for all diagnosed individuals</td>
                        </tr>
                      </tbody>
                    </table>
                  </table-wrap>
                </p>
                <p id="par0290">If the diagnosis of an infectee was triggered by contact tracing, then the infectee is considered to have a known transmission route. If both the symptom condition and the contact tracing condition are satisfied, the transmission route is considered to be known as well. The proportion of cases with known transmission routes reflects the proportion of cases that are identified by contact tracing.</p>
              </sec>
            </sec>
            <sec id="sec0150">
              <label>Appendix B</label>
              <title>Basic reproductive number, effective reproductive number and distribution of contacts in Scenario 1</title>
              <sec id="sec0155">
                <label>1</label>
                <title>) R0</title>
                <p id="par0295">Under the default conditions without any intervention, one index case infects approximately 1.93 agents (averaged over 100 simulations). The basic reproductive number R0 varied in each simulation with the same initial condition but different seeds and its histogram is shown below.</p>
                <p id="par0300">
                  <fig id="fig0030" position="anchor">
                    <graphic xlink:href="fx2_lrg"/>
                  </fig>
                </p>
              </sec>
              <sec id="sec0160">
                <label>2</label>
                <title>) Re</title>
                <p id="par0305">The trend of the effective reproductive number under no mitigation is shown below. The solid line is the median value of 100 simulations and the shadowed areas represent the 5th–95th percentiles. The values of Re drop drastically as the proportion of susceptible population decreases.</p>
                <p id="par0310">
                  <fig id="fig0035" position="anchor">
                    <graphic xlink:href="fx3_lrg"/>
                  </fig>
                </p>
              </sec>
              <sec id="sec0165">
                <label>3</label>
                <title>) Distribution of the number of transmissions per infector at day 33 (comparable to the distribution of contacts)</title>
                <p id="par0315">We supposed that the number of transmissions per infector during the earlier phase of the pandemic is comparable to the distribution of contacts as a large portion of the population are still susceptible. The function fitdist in R library (fitdistrplus) gives a negative binomial distribution with overdispersion for Scenario 1 as displayed in the figure below (aggregated from 100 experiments).</p>
                <p id="par0320">
                  <fig id="fig0040" position="anchor">
                    <graphic xlink:href="fx4_lrg"/>
                  </fig>
                </p>
              </sec>
            </sec>
            <sec id="sec0170">
              <label>Appendix C</label>
              <title>Formulae for different serial intervals and graphical illustration</title>
              <p id="par0325">TSI: Transmission serial interval (also known as the generation time)</p>
              <p id="par0330">COSI: Clinical onset serial interval (often referred as the serial interval)</p>
              <p id="par0335">DSI: Diagnostic serial interval or diagnosis interval</p>
              <p id="par0340">
                <fig id="fig0045" position="anchor">
                  <graphic xlink:href="fx5_lrg"/>
                </fig>
              </p>
              <p id="par0345">
                <fig id="fig0050" position="anchor">
                  <graphic xlink:href="fx6_lrg"/>
                </fig>
              </p>
            </sec>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
